Matrix Metalloproteinase-9 and Vascular Endothelial Growth Factor Expression Change in Experimental Retinal Neovascularization

Overview

Journal Int J Ophthalmol

Specialty Ophthalmology

Date 2016 Jul 2

PMID 27366678

Citations 10

Authors

Yu Di

Qing-Zhu Nie

Xiao-Long Chen

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the signal transduction mechanism of matrix metalloproteinase-9 (MMP-9) mediated- vascular endothelial growth factor (VEGF) expression and retinal neovascularization (RNV) in oxygen-induced retinopathy (OIR) model.

Methods: C57BL/6J mice were divided into four groups: control group, OIR group, OIR control group (phosphate-buffered saline by intravitreal injection) and treated group [tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) by intravitreal injection]. OIR model was established in C57BL/6J mice exposed to 75%±2% oxygen for 5d. mRNA level and protein expression of MMP-9, TIMP-1 and VEGF were measured by real-time polymerase chain reaction and Western blotting, and located by immunohistochemistry.

Results: Levels of MMP-9 and VEGF in retina were significantly increased in animals with OIR and OIR control group. Levels of TIMP-1 in retina was significantly reduced in animals with OIR and OIR control group. Furthermore, a significant correlation was found between MMP-9 and VEGF. Intravitreal injection of TIMP-1 significantly reduced MMP-9 and VEGF expression of the OIR mouse model (all P<0.05).

Conclusion: These results demonstrate that MMP-9-mediated up-regulation of VEGF promotes RNV in retinopathy of prematurity (ROP). TIMP-1 may be a potential target for the prevention and treatment of ROP.

Citing Articles

Critical roles of miR-21 in promotions angiogenesis: friend or foe?.

Saadh M, Jasim N, Ahmed M, Ballal S, Kumar A, Atteri S Clin Exp Med. 2025; 25(1):66.

PMID: 39998742 PMC: 11861128. DOI: 10.1007/s10238-025-01600-7.

Harnessing retinal phagocytes to combat pathological neovascularization in ischemic retinopathies?.

Ameln A, Sprott D Pflugers Arch. 2022; 474(6):575-590.

PMID: 35524802 PMC: 9117346. DOI: 10.1007/s00424-022-02695-7.

Butylphthalide Combined With Conventional Treatment Attenuates MMP-9 Levels and Increases VEGF Levels in Patients With Stroke: A Prospective Cohort Study.

Xiong Y, Liu J, Xu Y, Xie S, Zhou X, Cheng S Front Neurol. 2022; 12:686199.

PMID: 34987460 PMC: 8720749. DOI: 10.3389/fneur.2021.686199.

Pericytes of Indirect Contact Coculture Decrease Integrity of Inner Blood-Retina Barrier Model by Upgrading MMP-2/9 Activity.

Yang T, Guo L, Fang Y, Liang M, Zheng Y, Pan M Dis Markers. 2021; 2021:7124835.

PMID: 34630739 PMC: 8494570. DOI: 10.1155/2021/7124835.

miR-132 promotes retinal neovascularization under anoxia and reoxygenation conditions through up-regulating Egr1, ERK2, MMP2, VEGFA and VEGFC expression.

Zhang L, Tao L Int J Clin Exp Pathol. 2020; 10(8):8845-8857.

PMID: 31966751 PMC: 6965475.

References

Mohammad G, Siddiquei M . Role of matrix metalloproteinase-2 and -9 in the development of diabetic retinopathy. J Ocul Biol Dis Infor. 2013; 5(1):1-8. PMC: 3523102. DOI: 10.1007/s12177-012-9091-0. View

Kim W, Suh E . Retinal protective effects of resveratrol via modulation of nitric oxide synthase on oxygen-induced retinopathy. Korean J Ophthalmol. 2010; 24(2):108-18. PMC: 2850998. DOI: 10.3341/kjo.2010.24.2.108. View

Hapsari D, Sitorus R . Intravitreal Bevacizumab in Retinopathy of Prematurity: Inject or Not?. Asia Pac J Ophthalmol (Phila). 2015; 3(6):368-78. DOI: 10.1097/APO.0000000000000039. View

Egashira Y, Zhao H, Hua Y, Keep R, Xi G . White Matter Injury After Subarachnoid Hemorrhage: Role of Blood-Brain Barrier Disruption and Matrix Metalloproteinase-9. Stroke. 2015; 46(10):2909-15. PMC: 4589516. DOI: 10.1161/STROKEAHA.115.010351. View

Smith L, Wesolowski E, McLellan A, Kostyk S, Damato R, Sullivan R . Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994; 35(1):101-11. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Das A, McGuire P, Eriqat C, Ober R, DeJuan Jr E, Williams G . Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Invest Ophthalmol Vis Sci. 1999; 40(3):809-13. View

Lamoke F, Labazi M, Montemari A, Parisi G, Varano M, Bartoli M . Trans-Chalcone prevents VEGF expression and retinal neovascularization in the ischemic retina. Exp Eye Res. 2011; 93(4):350-4. DOI: 10.1016/j.exer.2011.02.007. View

Park K, Chen Y, Hu Y, Mayo A, Kompella U, Longeras R . Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage. Diabetes. 2009; 58(8):1902-13. PMC: 2712783. DOI: 10.2337/db08-1327. View

10.

Di Y, Zhang Y, Yang H, Wang A, Chen X . The mechanism of CCN1-enhanced retinal neovascularization in oxygen-induced retinopathy through PI3K/Akt-VEGF signaling pathway. Drug Des Devel Ther. 2015; 9:2463-73. PMC: 4425238. DOI: 10.2147/DDDT.S79782. View

11.

Kowluru R, Zhong Q, Santos J . Matrix metalloproteinases in diabetic retinopathy: potential role of MMP-9. Expert Opin Investig Drugs. 2012; 21(6):797-805. PMC: 3802521. DOI: 10.1517/13543784.2012.681043. View

12.

Kitajima K, Koike J, Nozawa S, Yoshiike M, Takagi M, Chikaraishi T . Irreversible immunoexpression of matrix metalloproteinase-9 in proximal tubular epithelium of renal allografts with acute rejection. Clin Transplant. 2011; 25(3):E336-44. DOI: 10.1111/j.1399-0012.2011.01421.x. View

13.

Sato T, Kusaka S, Shimojo H, Fujikado T . Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology. 2009; 116(9):1599-603. DOI: 10.1016/j.ophtha.2008.12.023. View

14.

Rundhaug J . Matrix metalloproteinases and angiogenesis. J Cell Mol Med. 2005; 9(2):267-85. PMC: 6740080. DOI: 10.1111/j.1582-4934.2005.tb00355.x. View

15.

Damico F . [Angiogenesis and retinal diseases]. Arq Bras Oftalmol. 2007; 70(3):547-53. DOI: 10.1590/s0004-27492007000300030. View

16.

Mi X, Yuan T, Ding Y, Zhong J, So K . Choosing preclinical study models of diabetic retinopathy: key problems for consideration. Drug Des Devel Ther. 2014; 8:2311-9. PMC: 4242133. DOI: 10.2147/DDDT.S72797. View

17.

Beranek M, Kolar P, Tschoplova S, Kankova K, Vasku A . Genetic variations and plasma levels of gelatinase A (matrix metalloproteinase-2) and gelatinase B (matrix metalloproteinase-9) in proliferative diabetic retinopathy. Mol Vis. 2008; 14:1114-21. PMC: 2426733. View

18.

De Rosa M, Messori A . The safety of bevacizumab and ranibizumab in clinical studies. Int Ophthalmol. 2015; 35(2):157-8. DOI: 10.1007/s10792-015-0043-0. View

19.

Setz C, Brand Y, Radojevic V, Hanusek C, Mullen P, Levano S . Matrix metalloproteinases 2 and 9 in the cochlea: expression and activity after aminoglycoside exposition. Neuroscience. 2011; 181:28-39. DOI: 10.1016/j.neuroscience.2011.02.043. View

20.

Wong R, Hubschman S, Tsui I . Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina. 2015; 35(4):675-80. DOI: 10.1097/IAE.0000000000000578. View